Clinical characteristics of patients
| Controls (n = 10) | Cystic fibrosis (n = 18) | |
|---|---|---|
| CFTR, cystic fibrosis transmembrane regulator; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; ND, not determined. | ||
| *p<0.001 compared with controls. | ||
| Results are expressed as mean (SD). | ||
| Other Gram negative bacteria include: Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkholderia cepacia. | ||
| Sex (male–female) | 3−7 | 8−10 |
| Mean (SD) age, year | 65.9 (10.5) | 29.3 (9.9)* |
| CFTR genotype, n (%) | ND | 18 (100) |
| F508 del/F508 del | — | 8 (44.4) |
| F508 del/other mutation | — | 6 (33.3) |
| Other/other mutations | — | 2 (11.1) |
| Other/ unidentified mutations | — | 2 (11.1) |
| Mean (SD) FEV1, % predicted | 96.8 (19.1)% | 19.5 (6.6)%* |
| Mean (SD) FVC, % predicted | 101.3 (23.0)% | 27.2 (9.4)%* |
| Airway colonisation, n (%) | 0 | 18 (100) |
| Pseudomonas aeruginosa | 0 | 17 (94.4) |
| Staphylococcus aureus | 0 | 6 (33.3) |
| Haemophilus influenzae | 0 | 0 |
| Other Gram negative bacteria | 0 | 6 (33.3) |
| Aspergillus fumigatus | 0 | 4 (22.2) |